§ The Daily · 11 articles live
Peptide therapy in the news.
What changed this week, this month — regulation, research, industry. Reported with primary sources, not press-release copy. New entries appear here as they ship.
All stories
By rubric.
- Lifting weights on tirzepatide: the first randomised trial Everyone in the trial lost about 22 kg. The half who lifted weights three times a week lost 3.57 kg of lean tissue instead of 4.67 kg, and got stronger rather than weaker. It is the first randomised test of the advice every clinic gives. 3 min read
- Retatrutide beat Ozempic 2 mg in its first head-to-head trial Lilly's experimental triple agonist lowered A1C more than Ozempic 2 mg and more than doubled its weight loss over 80 weeks in adults with type 2 diabetes. These are topline company figures, the drug is not approved, and the comparison that matters most is still running. 3 min read
- LegitScript will now certify sellers of six compounded peptides From November 2, LegitScript no longer refuses certification to sellers of BPC-157, TB-500, KPV, MOTS-c, Epitalon or Semax, if the product follows HHS's new policy. Which forms qualify, and what the seal does not mean. 2 min read
- HHS lets pharmacies compound six peptides, with conditions HHS says it will not take action against licensed pharmacies and physicians that compound BPC-157, TB-500, KPV, MOTS-c, Epitalon or Semax, while FDA decides through rulemaking whether to list them. The policy sets ten conditions: one peptide per product, specific routes for each, a certificate of analysis from an FDA-registered manufacturer, and adverse-event reporting. We checked two sellers' menus against them. 6 min read
- Two compounders recall GLP-1 injections over sterility The FDA's October 14 Enforcement Report lists 18 recalled compounded injections from two pharmacies, ten of them tirzepatide or semaglutide. Both firms had received FDA warning letters before. Here is what was recalled, what the recall class means, and what to check if you have a vial or syringe at home. 3 min read
- GLP-1 prices barely moved in 2026. Here is the data We recorded what nine GLP-1 sellers charged from January to August: from archived copies of their pages until late June, then every day. One of them actually changed its price. Three other movements our ledger recorded were us correcting what we had been counting as a price. 6 min read
- GLP-1 muscle loss: what Nestle's new push reveals Nestle says it is building products for people on Ozempic and Wegovy, starting with the muscle they lose. The loss is real and well measured — but only one intervention reliably reduces it. 8 min read
- FDA warning letters now reach research-peptide sellers Eleven sellers of "research use only" peptides have been cited since March. The run was a GLP-1 story until June, when one letter named Prostamax and gonadorelin. On 24 August the agency sent five more at once, and every one of them names PT-141 and tesamorelin alongside the GLP-1s. FDA reviewed all five websites in July — the month its own advisers voted to recommend six peptides for legal compounding. 10 min read
- FDA advisory panel overruled its reviewers on six of seven FDA's own scientists proposed no on all seven peptides. Its advisory committee voted yes on six — BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax — and rejected only Emideltide. The full vote record, from FDA's own broadcast, and what it changes. 8 min read
- FDA reviewers say no: seven peptides face 503A advisory vote Our pre-meeting preview of the July 23–24 PCAC review of seven peptides for the 503A bulks list, setting out FDA's position going in: for every one of them, the agency's proposed answer was the same. Do not add it. The committee has since voted the other way on six of the seven. 6 min read
- FDA cited 25 telehealth GLP-1 sellers in one wave The agency posted a batch of warning letters on June 16 — 25 of them aimed at compounded semaglutide and tirzepatide marketing. We pulled five of the letters and grouped what FDA actually objected to, who got named, and how it lines up with the parallel rulemaking, whose comment period was later extended to July 30. 6 min read